The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Nov. 28, 9:21 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #60. Cardiome Pharma Corp. Correvio LLC

Acquirer: Cardiome Pharma Corp. (CRME)
Acquiree: Correvio LLC
Details: Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has completed the acquisition of Correvio LLC ("Correvio"), a privately held pharmaceutical company headquartered in Geneva, Switzerland. Key benefits of the transaction include the following:

Correvio Pharma is engaged in the discovery, development and commercialization of drugs to treat or prevent cardiovascular diseases. Co.'s product, BRINAVESS™, is approved for marketing in the European Union, Iceland and Norway for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Co.'s clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Co. also has a few pre-clinical projects directed at various therapeutic indications that focus on modulating cellular proteins (ion channels) for cardiac diseases.

Open the CRME Page at The Online Investor »

Company Name: 
Correvio Pharma Corp
Website: 
www.cardiome.com
Sector: 
Drugs & Pharmaceuticals
 

Open the CRME Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree CRME Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.90 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 60 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.